Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

Core Insights - Outset Medical, Inc. has received 510(k) clearance from the FDA for its next-generation Tablo platform, which aims to enhance clinical outcomes in dialysis while reducing costs and complexity [1][2] - The new Tablo platform is the first hemodialysis system to comply with the FDA's latest cybersecurity guidance, reflecting the company's commitment to innovation and patient safety [2][3] Product Features - The next-generation Tablo platform is designed to provide enterprise-grade cybersecurity, reliability, and usability, with enhancements to hardware, operating system, and software [3][7] - The platform is expected to start shipping in the second quarter of 2026, and current users of Tablo will have the option to upgrade to the new cybersecurity features [4] Company Overview - Outset Medical is focused on transforming the dialysis experience with its innovative Tablo® Hemodialysis System, which integrates water purification and on-demand dialysate production [6] - The system is already trusted by over 1,000 healthcare facilities in the U.S. and has facilitated millions of treatments, showcasing its operational, clinical, and financial benefits [6]